Processing timeline
1
days
Filed
12 May 2026
Decision Due
25 June 2026
Est decision date: 10 June 2026. Based on 7 decided Wholesale & Distribution notifications.
Acquirer
Novartis
Target
Excellergy
Other parties
Novartis Finance Corporation, NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED, EXCELLERGY AUSTRALIA PTY LTD, NOVARTIS AUSTRALIA PTY LIMITED
Novartis Finance Corporation, via its subsidiary Elba Merger Sub, Inc., proposes to acquire 100% of Excellergy, Inc.'s capital stock. This share acquisition involves global medicines company Novartis, which supplies treatments in Australia, and a private biotechnology firm developing next-generation anti-immunoglobulin E therapies for allergic diseases.
